The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sravani Reddy Gantla
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sravani Reddy Gantla, a non-promoter shareholder of Oxygenta Pharmaceutical Limited, has sold 19,79,340 equity shares (5.35% of the company's equity capital) on April 16, 2025. The transaction was carried out off-market pursuant to a Memorandum of Understanding dated September 30, 2024, suggesting a pre-arranged private deal rather than an open-market sale. Following this disposal, her holding in the company dropped from 44,87,000 shares (12.13%) to 25,07,660 shares (6.78%). The filing was made under Regulation 29(2) and 29(3) of the SEBI (SAST) Regulations, 2011, which mandates disclosure for transactions exceeding 5% of shareholding.
This is a significant reduction in stake by a non-promoter shareholder, cutting her holding by more than half. While the seller is not classified as a promoter, the size of the off-market block deal could create short-term supply-side pressure if similar transactions are repeated, and the reduced float held by large shareholders may affect future liquidity in the stock.